Vijaya Diagnostic Q2 Net Profit Rises 35% YoY

Key Decisions and Approvals

1. Unaudited Financial Results: The Board approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The meeting commenced at 6:12 PM IST and concluded at 6:40 PM IST.

2. Management Appointment: Based on the recommendation of the Nomination and Remuneration Committee, the Board appointed Mr. Rahul Jain (Membership No. ACS A62949) as Company Secretary and Compliance Officer, designated as Key Managerial Personnel, pursuant to Section 203 of the Companies Act 2013 and Regulation 6(1) of SEBI LODR Regulations. The appointment is effective from November 3, 2026.

Financial Performance Highlights (Standalone)

Quarter Ended September 30, 2026 (Q2 FY27):

Revenue from operations: ₹24,200.20 lakh
Other income: ₹544.91 lakh
Total income: ₹24,745.11 lakh
Total expenses: ₹16,952.46 lakh
Profit before tax: ₹7,792.65 lakh
Tax expense: ₹2,000.19 lakh (Current tax: ₹1,943.00 lakh, Deferred tax: ₹57.19 lakh)
Profit for the period: ₹5,792.46 lakh
Other comprehensive income (net of tax): ₹46.58 lakh
Total comprehensive income: ₹5,839.04 lakh
Basic EPS: ₹5.63 (not annualized)
Diluted EPS: ₹5.61 (not annualized)

Half Year Ended September 30, 2026 (H1 FY27):

Revenue from operations: ₹46,053.91 lakh
Other income: ₹1,446.92 lakh
Total income: ₹47,500.83 lakh
Total expenses: ₹32,616.57 lakh
Profit before tax: ₹14,884.26 lakh
Tax expense: ₹3,777.04 lakh (Current tax: ₹3,600.34 lakh, Deferred tax: ₹176.70 lakh)
Profit for the period: ₹11,107.22 lakh
Other comprehensive income (net of tax): ₹63.70 lakh
Total comprehensive income: ₹11,170.92 lakh
Basic EPS: ₹10.79 (not annualized)
Diluted EPS: ₹10.77 (not annualized)

Financial Performance Highlights (Consolidated)

Quarter Ended September 30, 2026 (Q2 FY27):

Revenue from operations: ₹25,538.72 lakh
Other income: ₹495.10 lakh
Total income: ₹26,033.82 lakh
Total expenses: ₹18,092.17 lakh
Profit before tax: ₹7,941.65 lakh
Tax expense: ₹1,994.30 lakh (Current tax: ₹1,943.00 lakh, Deferred tax net: ₹51.30 lakh)
Profit for the period: ₹5,947.35 lakh
Other comprehensive income (net of tax): ₹58.35 lakh
Total comprehensive income: ₹6,005.70 lakh
Basic EPS: ₹5.78 (not annualized)
Diluted EPS: ₹5.76 (not annualized)

Half Year Ended September 30, 2026 (H1 FY27):

Revenue from operations: ₹48,636.91 lakh
Other income: ₹1,348.13 lakh
Total income: ₹49,985.04 lakh
Total expenses: ₹34,948.94 lakh
Profit before tax: ₹15,036.10 lakh
Tax expense: ₹3,778.64 lakh (Current tax: ₹3,600.34 lakh, Deferred tax net: ₹178.30 lakh)
Profit for the period: ₹11,257.46 lakh
Other comprehensive income (net of tax): ₹76.23 lakh
Total comprehensive income: ₹11,333.69 lakh
Basic EPS: ₹10.94 (not annualized)
Diluted EPS: ₹10.91 (not annualized)

Key Managerial Personnel Appointment Details

Name: Mr. Rahul Jain
Date of Appointment: November 3, 2026
Position: Company Secretary and Compliance Officer (Key Managerial Personnel)
Qualifications: Qualified Company Secretary and Associate Member of ICSI
Experience: Over six years in corporate secretarial functions, corporate governance, and regulatory compliances with extensive exposure to listed company regulatory framework
Expertise Areas: Companies Act 2013, SEBI LODR Regulations 2015, SEBI ICDR Regulations 2018, SEBI PIT Regulations 2015, SEBI SAST Regulations 2011, FEMA, and other applicable regulatory requirements
Previous Experience: Managing Board and shareholders' meetings, corporate restructuring, preferential allotments, FCCB issuances, ESOPs, share capital restructuring, regulatory disclosures, stock exchange compliances, and corporate governance matters

Capital Structure and Shareholding

Paid-up equity share capital (face value ₹1 each):
As of September 30, 2026: ₹1,029.98 lakh
As of June 30, 2026: ₹1,028.97 lakh
As of September 30, 2025: ₹1,027.25 lakh
As of March 31, 2026: ₹1,028.97 lakh

During Q2 and H1 FY27, the company issued 100,987 equity shares of face value ₹1 each on exercise of employee stock options.
During H1 FY27, the company granted 269,500 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee on May 7, 2026, and July 9, 2026.

Dividend Declaration

The Board of Directors at its meeting on May 7, 2026, proposed and recommended a dividend of ₹2 per equity share (200%) for FY 2025-26.
The dividend was approved by shareholders at the Annual General Meeting held on September 24, 2026.
The dividend was paid on October 7, 2026.

Business Acquisition

The Board of Directors on May 7, 2026, approved the acquisition of the business of Medinova Millennium MRI Services LLP (100% owned by the company) by way of a slump sale.
The transaction has been accounted for using the pooling of interest method as per Ind AS 103, Business Combinations.
The comparative financial information has been restated as if the business combination had occurred from the beginning of the preceding year.

Assets and Liabilities Position (Standalone as of September 30, 2026)

Total Assets: ₹168,866.32 lakh
Non-current assets: ₹123,969.35 lakh
Current assets: ₹44,896.97 lakh

Equity and Liabilities: ₹168,866.32 lakh
Total equity: ₹104,292.09 lakh
Non-current liabilities: ₹49,410.01 lakh
Current liabilities: ₹15,164.22 lakh

Cash Flow Position (Standalone H1 FY27)

Net cash generated from operating activities: ₹17,328.76 lakh
Net cash used in investing activities: ₹15,892.29 lakh
Net cash used in financing activities: ₹4,361.34 lakh
Net decrease in cash and cash equivalents: ₹2,924.87 lakh
Cash and cash equivalents at period end: ₹870.49 lakh

Auditor Review

The limited review of the unaudited financial results was conducted by B S R and Co. Limited, Chartered Accountants
An unmodified review report was issued on November 3, 2026

Additional Information

The company has one operating segment: "Diagnostic services"
Results are available at www.vijayadiagnostic.com, www.nseindia.com, and www.bseindia.com